One of the world’s leading journals in GU Oncology
Your kidney cancer research in basic science, translational medicine and clinical medicine is important. And you have a choice when you select a journal in which to publish your results. We invite you to submit your manuscript to Kidney Cancer, now Gold Open Access!
Here are 7 important reasons why:
- Focus on AX – the author experience: Practices and procedures designed to make the end-to-end article submission process straightforward, seamless and transparent. And we’re here to support you every step of the way.
- World class Editorial Board: Guidance by two internationally recognized leaders in the field ensures strict adherence to quality and ethical standards.
- Rigorous peer review: Providing insightful and constructive assessments of submitted work – Each submission is overseen by an Associate Editor knowledgeable in the specific subject area, evaluated by one of the Editors-in-Chief, and undergoes blind peer review.
- Rapid turnaround times: Expedited timeline for review and from acceptance to publication.
- Gold Open Access and compliance with funder mandates: Articles are immediately and permanently openly available online for readers to view, download, share, and reuse.
- Global reach: International in scope (authorship & readership) with increased visibility leading to higher citations.
- Discoverable content: Covered by Web of Science and Scopus.
This highly regarded journal is recognized for its excellent review articles, impactful research, important clinical trials coverage and patient advocacy.
In addition to subjects of interest featured in the Aims & Scope, Kidney Cancer is actively seeking contributions on these topics:
- Ablative therapies in kidney cancer
- Adjuvant or neoadjuvant systemic therapies in early-locally advanced kidney cancer
- Advances in molecular phenotyping of kidney cancer
- Cytoreductive approaches to metastatic renal cell cancer
- Innovative surgical approaches to kidney cancer
- Results of prospective clinical trials (regardless of stage, study phase, or whether results are positive or negative)
- Multidimensional biomarkers in kidney cancer
- Cancer health disparities and equity in renal cell cancer
- Molecular epidemiology of renal cell cancer
- New therapeutic agents with unique mechanisms of action
- Next generation imaging strategies for kidney cancer
- Novel immunotherapeutic approaches in kidney cancer
- Surveillance in kidney cancer
- Hereditary kidney cancer
- Minimal invasive approaches in kidney cancer
Any questions?
Just reach out to Editors-in-Chief at kca@iospress.com
Primo N. Lara, Jr., MD
University of California Davis, Comprehensive Cancer Center
Sacramento, CA, USA
Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands
Kidney Cancer partners with the
Kidney Cancer Association
